The Corporate Reputation of Pharma Companies, 2016: from the Perspective of 63 HIV/AIDS Patient Groups
Published Wednesday May 3rd 2017, as part of a set of 'extra' analyses offered by PatientView Format is PowerPoint (84 slides)
- The HIV/AIDS results are drawn from the opinions of 63 patient groups specialising in HIV/AIDS, based in 35 countries, and, in turn, are derived from the global review of pharma's corporate reputation (conducted November 2016 to early-February 2017).
- 8 pharma companies are included in this 2016 HIV/AIDS therapy-area 'extra' analysis: AbbVie I
Boehringer Ingelheim I Bristol-Myers Squibb I Gilead I Janssen I Merck & Co I Roche I and ViiV Healthcare.
How pharma is assessed for corporate reputation
Industry-wide questions: - How the pharma industry’s corporate reputation compares with that of other healthcare industries.
- How the pharma industry’s corporate reputation has changed over the past five years.
- How
good or bad the pharma industry is at various activities of relevance to patients and patient groups.
7 indicators for the corporate reputation of individual pharma companies: - Patient centricity.
- Information for patients.
- Patient safety.
- Usefulness of
products.
- Transparency.
- Integrity.
- Patient-group relationships (new for 2016).
[On transparency] “They could consult with patient-representative groups a lot more.” —Tasmanian Council on AIDS, Hepatitis and Related Diseases (TasCAHRD), Australia
[On patient information] “신약에 대한 홍보, 약의 효과및 부작용에 대해 환자단체들에게 정보를 제공해야 함.” [“Provide information to the patient groups on public relations, on drug effects, and on the side effects on the new drug.”] —Love4one, Korea
[On patient centricity] “Ya ninguna de ellas, ni otras que no figuran, tienen en Venezuela relación de cooperación con organizaciones y personas con VIH como la tuvieron en el pasado." [“None of them, nor the other companies we have not mentioned, have a cooperative relationship with HIV organisations and people with HIV in Venezuela —even though they did in the
past."] —Acción Solidaria (ACSOL), Venezuela
INDUSTRY-WIDE FINDINGS
- In 2016, HIV/AIDS patient groups show higher regard for pharma than patient groups from most other therapy areas.
44% of HIV/AIDS patient groups thought that the pharma industry had an "Excellent" or "Good" corporate reputation in 2016 (just 38% of patient groups across all therapy areas thought the same).
- HIV/AIDS patient groups ranked the generics drug industry as 1st among 8 healthcare-industry sectors for having a "Excellent" or "Good" corporate reputation in 2016. They ranked multinational pharma 4th.
High-quality products of use to patients% of total responses in 2016 describing pharma as “Excellent” or “Good” at producing high-quality products of use to patients
- HIV/AIDS patient groups were, on the whole, positive about many of the pharma industry's activities in 2016. Up to 76% stated that pharma was "Excellent" or "Good" at producing high-quality products of use to patients
[see chart].
- However, only 21% of HIV/AIDS patient groups stated that pharma was "Excellent" or "Good" at integrity (the figure among patient groups across all therapy areas was 35%, and 55% among haemophilia patient groups).
THE PARTNERSHIPS BETWEEN PHARMA COMPANIES AND PATIENT GROUPS
- 63 HIV/AIDS patient groups participated in the 2016 study. They came from Africa, Asia, Europe, North America, and Central & Latin America. The majority of the HIV/AIDS patient groups worked with at least two-to-four pharma companies (and many worked with more than that). As the chart above shows, one HIV/AIDS patient group worked with as many as 12 pharma companies. Half of the 63 HIV/AIDS patient groups worked with four-to-seven pharma companies.
Levels of familiarity among HIV/AIDS patient groups with the 8 pharma companies, 2016 % of respondent HIV/AIDS patient groups saying that they were familiar with the company
- The company with which HIV/AIDS patient groups were most familiar was Gilead (83% of respondent HIV/AIDS patient groups were familiar with the company).
INDIVIDUAL COMPANY FINDINGS
- ViiV Healthcare ranked overall 1st in 2016 for corporate reputation among the 8 pharma companies, when judged by HIV/AIDS patient groups.
- ViiV Healthcare also ranked 1st for six of the seven indicators of corporate reputation. The exception was the provision of high-quality products, for which HIV/AIDS patient groups ranked Gilead 1st.
CONTENTS AND DATA PROVIDED FOR EACH COMPANY
Contents - Executive summary.
- HIV/AIDS patient-group relationships with 8 pharma companies.
- Industry-wide findings from HIV/AIDS patient groups.
- HIV/AIDS patient groups on improving corporate reputation.
- Rankings of the 8 pharma companies among HIV/AIDS patient groups familiar with them.
- Positioning of the 8 pharma companies among partner HIV/AIDS patient groups.
- Profiles of the 8 pharma companies.
- Comments from respondent HIV/AIDS patient groups.
- Profile of the 63 respondent HIV/AIDS patient groups.
Tables - HIV/AIDS patient groups claiming familiarity, or which worked, with the company, 2016.
- Industry-wide performance among HIV/AIDS patient groups for corporate reputation:
- Compared with other healthcare sectors.
- Over time.
- For various activities.
- Recommendations on how industry can improve.
- Company profiles:
- Rankings among HIV/AIDS patient groups for the indicators of corporate reputation among patient groups familiar with the company, and which work/partner with the company.
- The company's average scores for the 7 indicators of corporate reputation, 2016 v. 2015.
- The company’s performance for the 7 indicators of corporate reputation.
- The company’s rankings among patient groups for the indicators of corporate reputation, 2016:
HIV/AIDS v. therapy wide; familiar with v. worked with.
- Percentage of the patient groups that worked with the company—but which also worked with other companies, 2016.
- How the company did at corporate reputation in different countries/regions, compared with its therapy-wide average.
For more information about the HIV/AIDS analyses, please use contact details below
|